Avidity Biosciences, Inc - Asset Resilience Ratio
Avidity Biosciences, Inc (RNAM) has an Asset Resilience Ratio of 67.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read RNAM liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Avidity Biosciences, Inc's Asset Resilience Ratio has changed over time. See what is Avidity Biosciences, Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Avidity Biosciences, Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Avidity Biosciences, Inc (RNAM) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.31 Billion | 67.13% |
| Total Liquid Assets | $1.31 Billion | 67.13% |
Asset Resilience Insights
- Very High Liquidity: Avidity Biosciences, Inc maintains exceptional liquid asset reserves at 67.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Avidity Biosciences, Inc Industry Peers by Asset Resilience Ratio
Compare Avidity Biosciences, Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC |
Biotechnology | 91585.83% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
Annual Asset Resilience Ratio for Avidity Biosciences, Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Avidity Biosciences, Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.13% | $1.31 Billion | $1.96 Billion | -14.83pp |
| 2024-12-31 | 81.95% | $1.28 Billion | $1.56 Billion | +16.68pp |
| 2023-12-31 | 65.27% | $410.27 Million | $628.55 Million | +22.95pp |
| 2022-12-31 | 42.32% | $270.33 Million | $638.80 Million | +22.42pp |
| 2021-12-31 | 19.90% | $85.09 Million | $427.58 Million | +17.90pp |
| 2020-12-31 | 2.00% | $6.68 Million | $333.90 Million | -- |
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more